Although our insight into antitumour immune responses has increased substantially in the past few decades, the development of immunotherapy for cancer has been hampered by challenges including the identification of optimal treatment strategies and methods to evaluate them. However, as Punt and colleagues discuss, the recent positive results of clinical trials with novel immunological drugs, as well as the unexpected finding of a positive interaction between immunotherapy and chemotherapy, may herald a new era for cancer immunotherapy.
- W. Joost Lesterhuis
- John B. A. G. Haanen
- Cornelis J. A. Punt